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Summary Mouse monoclonal antibodies PAb 240 and PAb 1801 which specifically immunoprecipitate p53
protein, were used to examine 27 fresh ovarian tumours (16 serous adenocarcinomas, six endometrioid
carcinomas, one mucinous adenocarcinoma, one mucinous borderline tumour and three benign adenomas).
Eleven out of 16 (69%) serous adenocarcinomas and one endometrioid tumour showed positive staining with
one or both antibodies and none of the mucinous or benign tumours stained with either antibody.
DNA from tumour and peripheral blood leukocytes was used to identify allelic deletions on chromosome
17p in tumours. 11/12 positively staining tumours showed less of heterozygosity (LOH) on 17p at the nearest
informative locus to the p53 gene.
In this series of ovarian tumours, LOH on 17p correlates closely with the aberrant expression of the p53
protein in a high proportion of advanced stage serous adenocarcinomas. This observation suggests that the
p53 tumour suppressor gene is involved in the evolution of epithelial ovarian cancer (EOC) and may have
prognostic significance.
Epithelial ovarian cancer (EOC) is the fourth commonest
cause of death in women in the UK (CRC Fact Sheet, 1988)
and USA and the leading cause of death from gynaecological
malignancy. This is mainly because it presents in the majority
of cases as advanced disease. It has a characteristic pattern
of transoelomic spread and infrequently spreads beyond the
peritoneal cavity. Various prognostic factors have been iden-
tified as influencing length of surviyal. These include the
extent to which debulking surgery can be achieved, the clini-
cal (FIGO) stage, presence of ascites, histological grade and
performance status (Lund, 1990; Heintz, 1988) and many of
these latter factors relate to how aggressive the tumour has
become.
In his review of recessive mechanisms of malignancy
(Green, 1988), Green commences with the statement 'cancer
is a genetic disease'. It is certainly true that sequential genetic
changes occur as tumours become more malignant and
advanced (Kern, 1989; Vogelstein, 1988). Many transforming
oncogenes have been identified associated with a variety of
malignancies including ovarian tumours (Kacinski, 1989;
Slamon, 1989); recently however much interest had focused
in solid tumours on the role of tumour suppressor genes
(Green, 1988; Ponder, 1988) which manifest themselves when
loss of function (either by mutation or deletion in both
alleles) leads to transformation and tumorigenesis.
Techniques using restriction fragment length polymorph-
isms (RFLP) and radiolabelled probes mapping to known
regions of the human genome (Hayes, 1989) allow detection
of submicroscopic deletions in tumour DNA. Peak areas of
allele loss point towards candidate tumour suppressor genes.
Chromosome 17p has been identified as one focus of allele
loss in a number of solid tumours including ovary (Eccles,
1990; Russell, 1990), breast (MacKay, 1988; Devilee, 1989),
and colon (Vogelstein, 1989).
The gene coding for the p53 protein is located on chromo-
some 17p 13.1 (Isobe, 1986). The gene product is a 53
kilodalton nuclear phosphoprotein (Lane, 1990) first identi-
fied in 1979 (Lane, 1979) as a host cell protein to which T
antigen is bound in SV40-transformed cells. Normal wild-
type p53 (p53-wt) acts as a suppressor of transformation in
mouse models (Finlay, 1989) but mutated p53 can act as a
dominant transforming oncogene (Hinds, 1989). Wild-type
p53 transfected into malignant cells can suppress tumour cell
growth (Baker, 1990a).
Point mutations in highly conserved areas of the gene
frequently lead to a conformational change which stabilises
the protein and allow it to accumulate in transformed cells.
The very low levels present in non-transformed cells are not
detectable using routine immunohistochemistry so positive
staining is highly suggestive of a mutant gene product
(Gannon, 1990). Studies in human colon (Baker, 1989;
Nigro, 1989) and lung (Takahashi, 1989; Iggo, 1990) tumours
and breast cancer cell lines (Bartek, 1990) have shown that
mutations in highly conserved regions of the p53 gene are
frequently associated with loss of heterozygosity at the
l7pl3.1 locus. Expression of mutant p53 protein has been
noted in a significant proportion of breast, colon and lung
tumours (Lane, 1990).
In this study, 24 ovarian carcinomas and three benign
tumours were examined for loss of heterozygosity on chro-
mosome 17p at or near the p53 gene locus. Immunohisto-
chemistry has been used as a screening test for mutant p53
protein implied by the presence of positive staining due to
accumulation of the protein. Frozen sections of the same 27
tumours have been examined using monoclonal antibodies
PAb 240 and PAb 1801 which recognise separate specific epi-
topes on the p53 protein. PAb 240 is specific for an epitope




Ovarian tumour tissue was collected during the surgical de-
bulking procedure. Samples were collected into dry ice then
stored at - 70C until processed. Peripheral blood samples
were collected into lithium-heparin tubes in the post-opera-
tive period. Verbal consent to the use of samples for analysis
was obtained from patients after full explanation of the
nature of the studies to be carried out. Five ml of blood was
used to establish a lymphoblastoid cell line and high mole-
cular weight DNA was extracted from the remainder of the
sample.
Tumour samples were divided three ways. One part was
formalin fixed and histology confirmed on routine haematox-
ylin and eosin stained sections. One part was used for extrac-
tion of high molecular weight DNA and the third part was
processed for immunohistochemical studies.
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Monoclonal antibodies
Two monoclonal antibodies were used, PAb 240 (Gannon,
1990) and PAb 1801 (Banks, 1989). These are both mouse
monoclonal antibodies which bind to p53 protein. PAb 1801
is specific for an epitope on the human p53 protein and
PAb 240 is specific for an epitope exposed only in mutant
p53 protein. Use of immunohistochemistry to screen for
mutant p53 protein can be expected to detect between
60-70% of mutants (D. Lane, B. Vogelstein - personal
communication).
Polymorphic probes
Five polymorphic probes within the 17p13 chromosomal seg-
ment were used to assess loss of heterozygosity in the tumour
compared to blood DNA. The probe pBHP53 maps to
17pl3.1 (Hoyheim, 1989) the same region as the p53 gene
(Figure 1) and lies within about 10 kb of the p53 gene (Dr
J.F. Brown, unpublished results). MCT 35.1 (MCT 35 in
Figure 1) (Nakamura, 1988) is about 2.5 cM and C3068
about 12.5 cM telomeric to BHP53. Information about allele
loss at or close to the p53 gene locus was sought first at the
BHP53 locus then, if this was uniformative, at the next
nearest informative locus to p53. Results were available for
two further more distal probes, YNZ 22.2 (YNZ 22 in Figure
1) YNH 37.3 (YNH 37 in Figure 1), but are not given here




High molecular weight (MW) DNA was extracted from
blood and tumour tissue. Whole blood cells were lysed in an
equal volume of 100 mM Tris, 20 mm sodium chloride, 1 mM
EDTA and 0.2% sodium dodecyl sulphate (SDS) then
phenol extracted, ethanol precipitated and resuspended for
treatment with RNAase and proteinase K in 0.2% SDS. A




















Figure 1 Schematic diagram of chromosome 17 showing the







Figure 2 Loss ofheterozygosity at the pBHP53 locus in tumours
G26 a and G34 b , G35 c.
and resuspension of 10 mM Tris 0.5 mM EDTA (TE) gave a
solution of high MW DNA which was quantified by spectro-
photometry.
Frozen tumour tissue was finely minced with a razor blade,
lysed for 24 h, treated with RNAase then proteinase K in
0.2% SDS at 37°C for 24 h then phenol/chloroform extracted
and ethanol precipitated before resuspending and quantifying
as for blood.
Restriction enzyme digestion and-hybridisation
Paired samples of blood and tumour DNA were digested to
completion with restriction endonucleases appropriate to the
probes used. Digested DNA was size fractionated on a 0.8%
agarose gel stained with ethidium bromide and photographed
to compare loading of DNA. DNA was denatured, transfer-
red to Hybond-N filter, neutralised and then UV-crosslinked.
Probes were labelled with 32P by random prime and hybrid-
ised in 5 x SSC, 5 x Denhardt's, 0.1% SDS, 0.1% NaPPi,
100 Lgml1I denatured salmon sperm at 65-68°C for 18-30
h, then non-specific radiation washed off. Autoradiography
was carried out at -70°C (Figure 2). Densitometry was used
as an additional check where allele loss was in any doubt on
visual assessments of radiographs. Greater than 50% loss of
density of one allele in tumour compared to blood was
accepted as a definitive loss of heterozygosity in all but one
case (G3) in which tumour sections contained more than
50% stromal tissue. All other tumours had much less than
50% stroma mixed with tumour tissue.
Immunohistochemistry
Frozen sections 5-7 microns thick were fixed in acetone and
allowed to dry. Non-specific binding was blocked in a normal
serum/BSA solution and sections incubated in primary anti-
body for 1 h at room temperature. Antibody binding was
detected using a standard alkaline phosphatase labelled strep-
tavidin-biotin method with Napthol ASMX phosphate/Fast
Red TR substrate/chromagen. Sections were counterstained
in Mayers haematoxylin and mounted in aqueous media.
Positive staining was seen as red granules overlying the nuclei
(Figure 3). Sections were interpreted without prior knowledge
of the results of LOH studies and scored according to the
amount of nuclear staining (Table I).42 D.M. ECCLES et al.
8 was scored, according to relative intensity, as weak ( + ),
moderately strong ( + + ), strong (+ + + ) or no staining
(-) (see Table I). In contrast to the serous tumours, the
pattern of staining in the only positive endometroid tumour,
of clear cell type (G4), was weaker and mainly cytoplasmic
with only occasional scattered nuclei showing positive stain-
ing. Altogether 12 tumours stained positive for p53. This
finding was associated with loss of heterozygosity at the
nearest informative locus to the p53 gene in 11 of these 12
tumours (Tables I and II). Eleven out of 12 positively stained
tumours were serous type (including serous, serous papillary
and serous cyst-adenocarcinomas). Information again from
the nearest informative locus to the p53 gene, showed that
allele loss occurred in four cases where no p53 positive
staining was seen in the tumour sections. One case (serous)
had positive staining and no detectable allele loss at BHP53.
In 11 cases, including one borderline and three benign
tumours, there was no evidence of aberrant p53 expression
and all informative loci had retained both alleles.
Figure 3 Staining produced using PAb 240 on frozen sections of
tumour tissue a, G21 ( x 230); b, G35 ( x 370); c, G41 ( x 230)
(negative). The mutant p53 protein stains as dense pink granules.
Results
Positive staining, in all cases of serous type carcinoma was
specifically located to the cell nucleus and homogeneous in
distribution throughout the malignant cells for each tissue
section; stromal cells never stained positive. The overall stain-
ing intensity between different tumours was compared by
incorporating a standard positive tumour into each run and
Statistical analysis (Table II)
The Chi-squared test showed a highly significant correlation
between positive p53 staining and allele loss at 17p13
(P<0.01).
Discussion
This study shows that aberrant expression of p53 protein is
common in ovarian cancer and correlates strongly with loss
of heterozygosity close to the p53 gene. It is likely that loss
of the p53 tumour suppressor gene is a key event in ovarian
carcinogenesis.
Clinical follow-up is too short to draw firm conclusions
about the prognostic significance of our findings but in this
series of unselected tumours (representative of the clinical
spectrum encountered) the serous adenocarcinomas had the
highest incidence of positive staining and LOH (62.5%). All
but one of the serous tumours (G17) were classed as poorly
differentiated, G17 was a moderate to well differentiated
tumour. All of the serous tumours except one (G8) presented
at an advanced clinical stage (Figo Stage III and IV). Other
histological types of carcinoma presented as stage 1 disease
except G23 which was a stage III endometrioid adenocar-
cinoma with omental involvement at presentation. The one
endometrioid carcinoma showing positive staining was of the
clear cell type but two others of this type showed no LOH
and were negative for mutant p53.
Recent work on colorectal tumours (Baker, 1990b) sug-
gests that point mutation in the p53 gene is the rate limiting
step in tumorigenesis, and the loss of the remaining wild type
allele occurs soon afterwards as a tumour passes from benign
to malignant.
In one of our cases, strongly positive staining with both
monoclonal antibodies was seen where both alleles were
retained at BHP53; in contrast four cases showed allele loss
of 17p with no immunohistochemical staining of p53 protein.
Although it is possible that allele loss has preceded p53
mutation in the latter three cases, it is also possible that
mutant p53 protein has not been recognised by the anti-
bodies used. Alternative explanations include a p53 mutant
with a short half life or a mutation to a stop codon in the
retained allele such that no p53 is produced by the tumour.
Direct sequencing of the p53 gene would clarify these points
and this is being undertaken.
It is apparent that loss of function of the p53 gene in this
group of tumours is seen most often in the advanced, poorer
prognosis disease and supports the view that these events
herald a phase of rapid uncontrolled growth of a tumour.
Further studies incorporating more early stage tumours of
the major histological types along with direct sequencing of
the p53 gene will help to increase our knowledge of the
overall pattern of events at the DNA level, which give rise to
the pattern of clinical disease we seen in ovarian cancer andp53 AS A TUMOUR SUPPRESSOR GENE IN OVARIAN CANCER 43
Table I Correlation of loss of heterozygosity at three loci on 17p with results of immunohis-
tochemistry using monoclonal antibodies against p53 protein
FIGO
Code C3068 MCT35.1 pBHP53 PAb 240 PAb 1801 Pathology stage
GIl 0 0 * + + + + Serous adenocarcinoma III
G15 * 0 0 + + + + Serous adenocarcinoma III
G19 0 0 * + + + + Serous adenocarcinoma III
G20 * * 0 + + + + Serous adenocarcinoma IV
G21 0 0 + ++ - Serous adenocarcinoma III
G24 0 0 * + + + + Serous adenocarcinoma III
G26 * * * + + + + Serous adenocarcinoma III
G32 * 0 O + + + + Serous adenocarcinoma III
G34 * 0 * + + + + Serous adenocarcinoma III
G35 * * * + + + +++ Serous adenocarcinoma III
G3 0 0 0 + + + + Serous adenocarcinoma III
G1 0 - - Serous adenocarcinoma III
G8 0 0 * - - Serous adenocarcinoma IIc
G9 * 0 0 - - Serous adenocarcinoma III
G17 0 0 0 - - Serous adenocarcinoma III
G41 0 0 * - - Serous adenocarcinoma III
G4 0 O * + + Endometrioid (clear cell) Ic
G23 0 0 - Endometrioid (clear cell) III
G28 O 0 e - - Endometrioid Ta
G30 0 0 0 - - Endometrioid (clear cell) I
G38 0 0 0 - - Endometrioid I
G42 0 0 0 - - Endometrioid Ic
G18 0 0 0 - - Mucinous adenocarcinoma Ia
G2 0 0 0 - - Borderline mucinous I
G37 0 0 0 - - Mucinous cystadenoma N/A
G7 0 0 0 - - Serous cystadenoma N/A
G10 0 0 0 - - Mucinous cystadenoma N/A
No aberrant staining (-); weak staining (+); staining of moderate intensity ( + + ); strong
staining ( + + + ). *, Loss of heterozygosity; 0, both alleles retained; 0, homozygous
(uninformative).
Table II Two by two table comparing aberrant p53 staining (any
intensity of + ) with loss of heterozygosity (LOH+) at the nearest
informative locus to the p53 gene
p53+ p53-
LOH+ 112 4 15
LOH 1 11 12
12 15 27
x2 (d.f.) = 11.4075; P<0.01. Aberrant p53 stain (p53+); no evidence
ofaberrant p53 accumulation (p53 -)loss ofheterozygosity (LOH-); no
LOH (LOH).
may have prognostic and even therapeutic implications for
the disease.
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